CompoAtlas

Complexe periménopause

Food supplement declared in France, decision dated 11 November 2026

Complexe periménopause (Onatera) is a food supplement declared in France. Status: declared in France, may be marketed. 4 rules of use apply to its ingredients (limits and warnings).

Brand
Onatera
Food business operator placing the product on the market
BioUltime
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
2 gélules
Directions for use
Prendre 2 gélules par jour avec un grand verre d'eau.
Intended populations
Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, History of breast cancer, Pregnant women, Taking antidepressants, Taking diabetes medication
Objectives stated by the manufacturer (these are not authorised claims)
Menstrual cycles

Declaration 382132, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Trigonella foenum-graecum L.GraineExtrait sec hydroalcoolique500 mg
Dioscorea oppositifolia L.RhizomeExtrait fluide hydroalcoolique100 mg
Glycine max. (L.) Merr.GraineExtrait sec hydroalcoolique100 mg
Turnera diffusa Willd. ex Schult.FeuilleExtrait sec hydroalcoolique100 mg
Crocus sativus L.StigmatesExtrait sec hydroalcoolique30 mg

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Pyridoxal 5'-phosphateVitamine B612 mg2 mg

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Se conformer aux conseils d’utilisation. Ne pas dépasser la dose journalière recommandée. Tenir hors de la portée des jeunes enfants. Ce produit ne peut remplacer une alimentation habituelle et diversifiée et un mode de vie sain. Déconseillé aux femmes enceintes ou allaitantes et chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein. Déconseillé chez les personnes sous traitement antidiabétique ou sous antidépresseur. Réservé aux adultes.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Trigonella foenum-graecum L.
    Read the warning, when it applies and the studies cited

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010; Mills et al. 2006; Hoffman 2003; Blumenthal et al. 2000).

    Sources cited by Health Canada (4)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. An Evidence-Based Approach. New York (NY): Taylor and Francis; 2006.

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Health Canada monograph dated 29 May 2026

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Topical

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 29 May 2026

  • Glycine max. (L.) Merr.
    Read the warning, when it applies and the studies cited

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : Onatera

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line